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Abstract
Atherothrombosis is a leading cause of cardiovascular mortality and long-term morbidity. Platelets 
and coagulation proteases, interacting with circulating cells and in different vascular beds, modify 
several complex pathologies including atherosclerosis. In the second Maastricht Consensus 
Conference on Thrombosis, this theme was addressed by diverse scientists from bench to bedside. 
All presentations were discussed with audience members and the results of these discussions were 
incorporated in the final document that presents a state-of-the-art reflection of expert opinions and 
consensus recommendations regarding the following five topics:
1. Risk factors, biomarkers and plaque instability: In atherothrombosis research, more 
focus on the contribution of specific risk factors like ectopic fat needs to be considered; 
definitions of atherothrombosis are important distinguishing different phases of 
disease, including plaque (in)stability; proteomic and metabolomics data are to be 
added to genetic information.
2. Circulating cells including platelets and atherothrombosis: Mechanisms of leukocyte 
and macrophage plasticity, migration, and transformation in murine atherosclerosis 
need to be considered; disease mechanism-based biomarkers need to be identified; 
experimental systems are needed that incorporate whole-blood flow to understand how 
red blood cells influence thrombus formation and stability; knowledge on platelet 
heterogeneity and priming conditions needs to be translated toward the in vivo 
situation.
3. Coagulation proteases, fibrin(ogen) and thrombus form ation: The role of factor (F) XI 
in thrombosis including the lower margins of this factor related to safe and effective 
antithrombotic therapy needs to be established; FXI is a key regulator in linking 
platelets, thrombin generation, and inflammatory mechanisms in a renin-angiotensin 
dependent manner; however, the impact on thrombin-dependent PAR signaling needs 
further study; the fundamental mechanisms in FXIII biology and biochemistry and its 
impact on thrombus biophysical characteristics need to be explored; the interactions of 
red cells and fibrin formation and its consequences for thrombus formation and lysis 
need to be addressed. Platelet-fibrin interactions are pivotal determinants of clot 
formation and stability with potential therapeutic consequences.
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4. Preventive and acute treatment of atherothrombosis and arterial embolism; novel ways 
and tailoring? The role of protease-activated receptor (PAR)-4 vis á vis PAR-1 as target 
for antithrombotic therapy merits study; ongoing trials on platelet function test-based 
antiplatelet therapy adjustment support development of practically feasible tests; risk 
scores for patients with atrial fibrillation need refinement, taking new biomarkers 
including coagulation into account; risk scores that consider organ system differences 
in bleeding may have added value; all forms of oral anticoagulant treatment require 
better organization, including education and emergency access; laboratory testing still 
needs rapidly available sensitive tests with short turnaround time.
5. Pleiotropy of coagulation proteases, thrombus resolution and ischaemia-reperfusion: 
Biobanks specifically for thrombus storage and analysis are needed; further studies on 
novel modified activated protein C-based agents are required including its 
cytoprotective properties; new avenues for optimizing treatm ent of patients with 
ischaemic stroke are needed, also including novel agents that modify fibrinolytic 
activity (aimed at plasminogen activator inhibitor-1 and thrombin activatable 
fibrinolysis inhibitor.
Keywords
atherothrombosis; arterial thrombosis; coagulation; platelets; antiplatelet therapy; anticoagulants; 
atherosclerosis; ischaemic stroke; atrial fibrillation; myocardial infarction
Introduction
During the second Maastricht Consensus Conference on Thrombosis (MCCT), 
atherothrombosis and cardiovascular disease (CVD) were tackled from different angles by 
basic and clinical scientists, younger as well as seasoned experts from an international 
background. Concise presentations on subtopics within a larger theme (www.mcct.eu) were 
held, followed by discussion sessions (presenters, students, other attendants) to outline 
targets for future research. Based on a plenary synthesis of all sessions, a final consensus 
document summarizing all topics and recommendations (Fig. 1)) was drafted based on the 
notes from all contributing authors and condensed into this position paper. This document 
does not intend to provide a comprehensive overview of the field; primarily it reflects the 
personal interests and opinions of the experts and input from the audience.
Risk Factors, Biomarkers and Plaque Instability
Atherothrombosis occurs in the course of atherosclerosis, a condition driven by chronic 
inflammation.1,2 Current concepts on ‘thomboinflammation’3 also fit in the context of 
atherothrombosis driven by the interplay between inflammation and coagulation as a critical 
mechanism.4,5 Obesity is one of the main drivers of chronic inflammation in atherogenesis.
Obesity, Ectopic Fat and Thromboinflammation
Obesity is a worldwide health problem with increasing prevalence.6 Although obesity is 
heterogeneous, approximately 30% of obese individuals remain healthy into old age.7 
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Ectopic fat accumulation rather than overall obesity is responsible for increased 
cardiometabolic risk and is a better predictor for CVD, including atrial fibrillation (AF) and 
heart failure.8–10 Ectopic fat refers to fat that accumulates in or around specific organs or 
compartments and include abdominal viscera (visceral fat), liver (intrahepatic fat), heart 
(pericardial fat), and blood vessels (perivascular fat). Recent findings support an independent 
contribution of ectopic fat deposition to cardiovascular risk.11
Strengthening research on the contribution of ectopic fat depots to cardiometabolic risk and 
risk of CVD is necessary. Adipose tissue is a dynamic endocrine organ consisting of 
adipocytes and nonadipocytes including immune cells. Excess ectopic fat may exert harmful 
effects by direct lipotoxicity, or by a chronic proinflammatory effect, at both the local and 
systemic level. The impact of ectopic fat on CVD might occur at different stages of disease 
progression. The growth of fat mass leads to changes in the adipocyte cell size and number 
as well as in the pattern of immune cells with an exacerbated presence of macrophages and 
lymphocytes, with a proinflammatory phenotype. This leads to a deregulated expression of 
bioactive molecules including cytokines and adipokines, which contribute to inflammation, 
endothelium dysfunction, progression of atherogenesis, and a prothrombotic state, all 
increasing cardiovascular risk.12,13 Further research should unravel differences between fat 
depots in cell composition, inflammatory response, and cell-signaling pathways and 
ultimately how this translates into atherosclerosis.
Traditionally, obesity is determined through the body mass index (BMI), but clearly, the 
pattern of fat distribution is more important than the absolute amount of stored fat; it is 
conceivable that ectopic fat becomes the diagnostic and therapeutic target in cardiometabolic 
disorders shifting the focus from quantity (obesity) to quality (dysfunctional fat).14 Current 
methodologies for tracking ectopic fat distribution are limited to expensive imaging 
techniques (e.g. computed tomography [CT], magnetic resonance imaging [MRI]).15
Genetics and Cardiovascular Disease
For the advancement of prevention in CVD, improving the accuracy of genetic risk 
stratification will be of major importance. Single nucleotide polymorphisms increasing the 
risk of CVD via interference with inflammation, lipids, blood pressure, nitric oxide/cyclic 
guanosine monophosphate signaling, vascular remodelling, and plaque formation have been 
detected.16 Several research groups have addressed the implementation of these genetic 
variants into genetic risk models for arterial thrombosis.17,18 Nevertheless, current 
guidelines recommend only standardized assessment of family history of premature CVD 
and discourage the generalized use of DNA-based test for risk assessment.19 Since current 
treatm ent concepts predominantly focus on the therapy of disease phenotypes and our 
understanding of organ-specific gene translation is still limited, more efforts are needed to 
unravel gene-gene and gene-environment interactions in a systems-medicine-oriented 
approach.
To improve current knowledge about the translation of genotype into phenotype, integrative 
data analysis and deep clinical phenotyping for subclinical disease will be required. 
Therefore, epigenetic, proteomic, and metabolomic information should be analysed in 
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conjunction with genomic data to improve the understanding of the pathophysiology of 
CVD and to advance the prevention of CVD. Considering the required sample size and the 
expertise in ‘omics-technology’ and bioinformatics needed to study the complex interplay of 
genetic variation and its functional role, combined efforts (e.g. in consortia) will be needed. 
These efforts should be accompanied by an interdisciplinary discussion on ethical aspects, as 
advancements in the field of genetics will entail novel ethical demands for regulatory 
authorities, health care providers and patients.
Phenotyping the Atherothrombotic Lesion
Tissue composition of plaques rather than the degree of luminal stenosis determines the 
vulnerability of an athero-sclerotic plaque to develop disruption followed by thrombosis.20 
A thin fibrous cap, large lipid-rich necrotic core, low amount of collagen, and high 
inflammatory activity are major determinants of plaque vulnerability.2,21 Tissue 
characteristics of high-risk plaques can now be visualized with the use of invasive vascular 
imaging techniques, which has created considerable progress in defining the composition of 
plaques in patients. Intravascular ultrasound with virtual histology analysis provides a cross-
section view of the entire vessel wall and allows to detect the thickness of a fibrous cap and 
size of a lipid core.22 Optical coherence tomography (OCT) provides higher resolution 
imaging but limited depth penetrance, with more detailed information on the near lumen 
morphology such as fibrous cap structure, superficial macrophage accumulations, or plaque 
rupture.23 However, imaging of the activity and specific location of inflammatory cells and 
their secretory products in plaques is less succesful.24 Some progress has been made in 
experimental settings. For example, a critical step in the destabilization of plaques is the 
secretion of matrix-degrading metalloproteinases (MMPs) by inflammatory cells.25 With the 
use of single-photon emission computed tomography/micro-CT imaging with radiolabelled 
metalloproteinase inhibitors, MMP activity could be detected in animals (rabbits) in a 
noninvasive manner.26 And in humans, application of near-infrared autofluorescence 
imaging appeared successful in detecting fluorescence of naturally occurring molecules in 
necrotic cores of high-risk plaques, which provides some information about the biological 
activity inside a lesion.27 Such noninvasive imaging techniques describing plaque phenotype 
over time could elucidate the relation between inflammation, plaque vulnerability, and 
clinical events. Still, up to now it remains a challenge to predict plaque rupture in individual 
patients.28 Therefore, there is a call for new definitions and risk assessment strategies 
regarding atherothrom-bosis. Besides morphology of plaques, vulnerability of blood (e.g. 
hypercoagulability and inflammation) is a contributor to atherothrombosis.28
There is a knowledge gap with respect to biomarkers of ongoing plaque destabilization. 
Pathologic analysis of thrombectomy specimens retrieved from acute myocardial infarction 
(AMI) patients has revealed huge variations in the propagation of thrombosis after onset of 
plaque rupture. Stratification of the so-called fresh (<1 day) and old(>5 days) thrombi 
should also be considered.29 Old thrombus is an independent predictor of mortality in AMI 
patients, which probably relates to their fragile structure and inherent risk of embolization.30 
For example, MMP content of such thrombi is much higher than in the underlying plaques. 
Therefore, also thrombus instability appears a matter of concern and the cellular pathways 
leading to thrombus healing (stabilization) or otherwise embolization or progression to full 
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luminal occlusion need to be further elucidated. Combining morphological characteristics 
with bio-markers of vulnerable blood, plaque vulnerability, and thrombus instability should 
result in a pan-arterial approach in which atherothrombotic risk establishment becomes more 
accurate.
Utility of Biomarkers
Meta-analyses of prospective studies have established positive associations of circulating 
levels of fibrinogen, von Willebrand factor (VWF), fibrin D-dimer, and tissue plasminogen 
activator with risk of coronary heart disease (CHD) and stroke. These data support the 
concept of coagulation activity as an important contributing mechanism in the processes of 
atherosclerosis as well as thrombosis. The biomarker data are not yet comprehensive and in 
particular further studies are required to establish the associations of other coagulation 
proteins, including those from the contact system, with risk of CHD and CVD.31 Given their 
importance as potential therapeutic targets in CVD, additional biomarkers for vWF, factors 
VIII, IX, XI, and XII merit further research.32
D-dimer level is associated with risk of stroke in patients with AF,33 irrespective of 
anticoagulant drugs.34 Prospective studies are required to establish its potential role in risk 
stratification, its relationship to other coagulation activation markers (e.g. prothrombin F1 
+ 2), and other biomarkers (e.g. CRP, troponin and pro-NT-BNP).35 These may inform 
future management into two directions. One route concerns the optimized selection of 
patients who benefit most from anticoagulant treatment (e.g. the discussion in theme 4 on 
the need for improved selection of patients with AF). A second direction would involve, if 
possible, dose titration in high-risk subjects. An indication for its potential comes from 
studies showing that D-dimer level while on anticoagulation predicts ischaemic stroke risk in 
patients with AF.36
Recommendations from Theme 1
• Future research should focus on identifying biomarkers of ectopic body fat 
content and distribution and on developing clinical algorithms including ectopic 
fat assessment for cardiovascular risk stratification.
• Genetic risk stratification, including family history, gene-gene and gene-
environment interactions, as well as comorbidity needs to be explored; 
integrative data analysis and deep phenotyping are crucial. Proteomic and meta-
bolomic data need to be implemented with genomic data in multicentre trials.
• Develop new definitions and risk assessment strategies for atherothrombosis, 
potentially combining morphological characteristics with biomarkers of 
‘vulnerable blood’ as well as for plaque destabilization to optimize athero-
thrombotic risk stratification.
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Circulating Cells Including Platelets and Atherothrombosis
New insights in the diversity and functionality of monocytes (macrophages), leukocytes, and 
platelets were discussed. The importance of microvesicles (MVs) was recently discussed in 
this journal.37
Leukocytes in Atherothrombosis
The importance of leukocytes in the pathophysiology of atherosclerosis has been well 
recognized. T lymphocytes and monocytes/macrophages are abundantly present in 
atherosclerotic lesions, and strategies that modulate the abundance of these cells show strong 
effects on the extent of atherosclerosis, at least in mouse models. Also B cells, divided into 
two main families, provide important protective effects against atherosclerosis (B1), while 
B2 cells are thought to be atherogenic.38,39 Mouse models have also revealed roles of 
polymorphonuclear cells, most notably neutrophils and mast cells, in the pathophysiology of 
atherosclerosis.40,41 Lineage tracing and specific labelling of leukocyte subtypes in vivo, 
along with innovative strategies to deplete certain leukocyte subsets in mice, have led to the 
identification of important contributions of almost any leukocyte subtype tested.39,42–44 
However, there is still no viable therapeutic or preventive strategy that directly targets 
leukocytes.
The puzzle is more complex than initially assumed. First, the cell content of the plaque is 
quite dynamic. Although influx of leukocytes is still believed to be crucial in plaque 
development, emigration of immune cells from plaques (e.g. to nearby lymphoid organs) 
also plays a role.45 Interestingly, mouse studies revealed that local proliferation outweighs 
infiltration and is the major determinant of macrophage numbers in the plaque.46 Smooth 
muscle cells (SMCs) that are highly abundant in plaques migrate from the media to the 
intima, where they proliferate. SMC can also turn into macrophage-like cells with 
phagocytic activity and the excessive ingestion of lipoproteins causes them to degenerate 
into foam cells, much like classical macrophages.47,48 In general, mouse models of 
atherosclerosis will remain to have utility, but their importance in basic pathophysiologic 
research might decline, as the emergence of the ‘omics’ class of technology (e.g. genome-
wide association studies, proteomics and RNA sequencing) will gradually take over their 
roles in human cohorts. This might even lead to the identification of drug principles 
targeting leukocyte dynamics, once its role in plaque development is fully understood.
Macrophages and Signaling Effects
Monocytes and neutrophils contribute to venous thrombosis.49 Recent studies show that 
myeloid cell tissue factor (TF) activation in thrombosis is linked to complement activation.50 
Remarkably, complement factor (C) 3 plays a pivotal role in platelet activation independent 
of full complement activation downstream of C5. C5 nevertheless is crucial for outer 
membrane phosphatidylserine exposure and activating TF prothrombotic activity, as 
previously also demonstrated for complement fixing antibodies causing thrombotic 
complications in stem cell therapy.51 Protein disulphide isomerase pathways are necessary 
for affinity maturation of TF and phosphatidylserine exposure but is not sufficient to render 
MV-associated TF fully prothrombotic.52 Complement-dependent release of MV from 
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monocytes in LPS-stimulated whole blood produces TF which due to its high affinity is 
already in complex with its ligand FVIIa.
Venous thrombosis and atherothrombosis are likely driven by distinct but partially 
overlapping pathophysiological interactions of blood and vessel wall cells.53 
Atherothrombosis is closely tied to inflammation and interleukin 1β (IL1β) is one of the 
inflammatory cytokines implicated as a risk factor for arterial occlusive events. Indeed, the 
recently published CANTOS trial provides proofofconcept evidence in showing clinical 
efficacy of the administration of an anti-interleukin-1β antibody in reducing cardiovascular 
events.54 Macrophages in atherosclerotic lesions are rich sources of TF, but macrophage-
expressed TF is also largely in a noncoagulant state. Cell injury signals, specifically ATP 
triggering the prothrombotic P2 × 7 receptor,55 induce a thioredoxin-reductase-dependent 
inflammasome and caspase-1 activation in primed macrophages. Active caspase-1 
simultaneously generates active IL1β and is responsible for the terminal release step of 
highly prothrombotic MV carrying active TF.56 These data provide evidence for a direct 
mechanistic coupling of thromboinflammatory pathways. It will be of interest to further 
study whether this close coupling of inflammation and coagulation is common to other 
activators of the inflamma-some. Since macrophages in atherosclerotic lesions express the 
P2 × 7 receptor,57 a possible role of this receptor in lesion thrombogenicity should be 
investigated.
Coagulation also directly influences atherosclerotic lesion progression through effects on 
leukocytes.58 It is notable that expression of coagulation factors by macrophages is not 
restricted to TF. Lung and peritoneal macrophages express FVII in mouse and man59,60 and 
tumour macrophages produce FVII and FX.61 It is an intriguing possibility that macrophage 
phenotypes in atherosclerosis are directly regulated by signaling through protease-activated 
receptors (PARs). PAR2 in particular has been implicated in the regulation of macrophage 
activation62 and chronic inflammation in obesity.63 It will be of interest to determine 
whether coagulation factors synthesized by macrophages have effects on lesions 
progression, stabilize plaque structure, or contribute to lesion thrombogenicity. While 
coagulation inhibitors may broadly interfere with thrombosis-related pathways, experimental 
studies can more precisely define the contributions of intravascular and vessel wall 
compartments to lesions progression. Translating experimental findings into the clinic will 
require the development of new diagnostic, biomarker, and imaging approaches based on 
these mechanistic studies in thromboinflammation.
Red Blood Cells
In healthy humans, red blood cells (RBCs) occupy approximately 35 to 45% of the blood 
volume and elevated haematocrit has been associated with increased risk of both arterial and 
venous thrombosis (reviewed in Byrnes and Wolberg64). RBCs have biophysical and 
biochemical properties that contribute to thrombus formation. For example, RBCs are 
majordeterminants of blood viscosity, and increased viscosity has been associated with risk 
of cardiovascular events.65 In vitro studies suggest RBCs promote platelet interactions with 
the vessel wall,66,67 expose phosphatidylserine, support thrombin generation,68–72 bind 
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fibrinogen and fibrin, and decrease clot permeability73 and susceptibility to fibrinolysis.74 
Studies are needed to determine whether RBCs are causative in thrombus formation.
Although RBCs are present in both arterial and venous thrombi, their local function as well 
as their beneficial or pathological effects during thrombus evolution remains unknown. For 
example, heme deposited by decomposing or phagocytized RBCs may alter recruitment or 
function of other blood cells within the clot. Compaction of RBCs by platelet-mediated 
contractile force may stabilize thrombi and prevent embolization, but may prolong thrombus 
resolution. Experimental systems that incorporate blood flow, RBCs, platelet-mediated 
contraction, thrombin generation, and fibrinolysis are needed to understand how RBCs 
influence thrombus formation and stability.
Platelet Pleiotropy: Different Platelets, Different Functions
The concept of interplatelet heterogeneity75 is receiving increased interest. Platelets from an 
individual donor can differ in glycoprotein receptors expression levels and activation. 
Circulating platelets differ in mRNA content and capacity to translation, depending on their 
life time.76 Furthermore, platelets undergoing secretion can differ in the process of secretory 
granule fusion and exocytosis.77 On the other hand, platelets assembling in a growing 
thrombus diverge into (1) aggregated and contracted platelets of the thrombus core; (2) 
transiently adhered platelets of the outer thrombus shell; and (3) highly activated, 
procoagulant platelets in thrombus patches.75 This raises the intriguing question if the 
known pleiotropy in platelet functions implies that different populations of platelets are 
‘specialized’ in carrying out different functions. Several key elements in the life of platelets 
that are worth further investigation can be identified:
1. Difference between individual megakaryocytes and platelets. Despite 
visualization of (pro)platelet production in the bone marrow,78 it is unknown 
how megakaryocytes regulate the numbers of receptors per formed platelet. A 
current assumption is that a certain megakaryocyte produces similar 
(pro)platelets, but cultured megakaryocytes, even when produced from a single-
cell clone of hematopoietic precursors, show a remarkably large inter-cellular 
variability in surface receptor expression.79 This raises the possibility that 
different megakaryocytes in the bone marrow can form different ‘types’ of 
platelets.
2. Priming o f platelets (macroenvironment). Due to the presence of circulating 
hormones or other biomolecules, platelets can be primed to become more or less 
responsive to agonists.80 Priming can occur rapidly, and be followed by a 
prolonged period of sensitization or desensitization.81 Given the differences in 
makeup of individual platelets, some platelets may be more prone to priming 
than others. Both acute and chronic disease conditions may act as primers, either 
through exposure to tissue damage or through inflammatory mediators or 
pathogens.
3. Platelet populations in a thrombus (microenvironment). Densely aggregated and 
contracted platelets have been observed in the thrombus core, surrounded by an 
outer shell of more loosely attached platelets.82 Surrounding the aggregated 
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platelets, patches of highly activated platelets are seen with a specialized 
function in coagulation.75 Likely, the microenvironment (e.g. the direct exposure 
of platelets to collagen and thrombin) plays a role in this platelet heterogeneity.
4. Platelet age and size. Platelets circulate in the blood stream for 7 to 11 days. 
There is debate whether newly formed platelets are larger in size and more active 
than aged platelets. Such associations have been measured, but these are weak. 
Increased mRNA content of the younger platelets may direct platelet function 
and fate and even the vesiculation of platelets.
5. Platelet heterogeneity in vivo versus in vitro. The properties and even the 
populations of isolated platelets can differ (e.g. with respect to priming) from the 
properties of platelets circulating in the blood. Moreover, in vivo pre-activated 
platelets will be more prone to being cleared than inhibited platelets, whereas 
both can stay in suspension after isolation.81 This brings about a need for new 
technologies to study single-cell activation properties of platelets in vivo and in 
vitro, and a requirement for standardized isolation of platelets without affecting 
their priming state.
Recommendations from Theme 2
• Address mechanisms of leukocyte plasticity, migration, and transformation in 
murine atherosclerosis; various ‘omics’ technologies have the potential to take 
over the role of mouse models in human cohorts.
• Characterize the role of haemostatic factors in macrophages related to 
inflammation and atherothrombosis; develop mechanism-based biomarkers.
• Investigate the causal contribution of RBCs in thrombus formation.
• Incorporate whole blood flow in experimental systems to assess how RBCs 
influence thrombus formation and stability.
• Improve knowledge on platelet heterogeneity, how this translates into the 
formation of platelet populations by megakaryocytes, how to translate from 
single-cell (platelet, megakaryocyte) assays to the in vivo situation? Investigate 
how platelet priming fits into the pathogenesis of thrombotic disease (cause or 
consequence?).
Coagulation Proteases, Fibrin(Ogen) and Thrombus Formation
Factor XI
Factor XI (FXI) is a pivotal protein in the coagulation cascade, as it links the contact system 
with thrombin and fibrin formation, and it also determines the flux through the coagulation 
cascade after TF exposure via thrombin-mediated FXI activation.83 Drugs targeting FXI can 
be effective for thrombosis prevention, but there are no data showing that FXI targeting is 
useful in the treatment of thrombosis. An intervention study in humans who underwent total 
knee replacement demonstrated that reducing FXI levels by antisense oligonucleotides 
(ASO) was effective and safe.84 This study was carefully chosen, since knee replacement 
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introduces a medical device, which likely activates the contact system. Furthermore, the TF 
concentration in knees is very low, meaning that the amplification of thrombin formation via 
FXI becomes relatively important.85
The bleeding tendency in FXI deficiency is most often trauma related especially in tissues 
with high local fibrinolytic activity, while spontaneous bleeding is rare, and therefore low 
levels of FXI appear to be safe. Preclinical and clinical studies suggest that complete 
deficiency is not necessary to effectively prevent thrombosis; a level of 20 to 30% FXI is 
effective and expected to result in less bleeding compared with complete inhibition.
The optimal approach to target FXI is still debated.86 Vaccination (probably not reversible) 
and ASO have the disadvantage of a slow onset of action. The use of small molecules and 
(monoclonal) antibodies requires additional studies, also considering potential off-target 
effects of these approaches.
Coagulation (Factor XI) and Its Link with Platelets and Hypertension: A Novel Risk 
Mechanism
Recent experimental and early clinical data suggest that targeting FXI could be effective in 
treating vascular inflammatory conditions that go beyond treating clotting disorders. FXI 
deficiency improved survival in polymicrobial sepsis87 and protected from disease 
progression in atherosclerotic mice.88 Individuals with congenital FXI deficiency are 
partially protected from myocardial infarction and stroke, both sequels of chronically 
increased blood pressure.89 FXI ASO application prevented arterial hypertension and 
reduced established hypertension in animal models. This effect was connected to 
interruption of the thrombin-FXI amplification loop involving glycoprotein (GP)Ibα on 
platelets, attenuating the proinflam-matory state of platelets and reducing vascular 
accumulation of inflammatory leukocytes, endothelial dysfunction, and tissue remodelling in 
response to high blood pressure. The FXI-dependent platelet-localized amplification of FII 
was validated in humans with uncontrolled hypertension.90
Since thrombin propagation is essential in the observed non-clotting-related effects, 
thrombin signaling, which is likely mediated through PARs, must be further explored. Since 
PAR-1 is expressed on monocytes, endothelial cells and SMCs alike, the thrombin-signaling 
through PAR-1 needs to be investigated in greater detail to understand possible beneficial 
off-target and/or disease modifying effects of direct thrombin inhibitors like dabigatran. 
However, RELY investigators91 so far have not reported on alterations in blood pressure in 
patients on dabigatran treatment.
If the FXI-mediated effects were all related to propagation of thrombin formation, patients 
with haemophilia A or B should also have lower blood pressure. However, the contrary is the 
case; this may be due to inflammatory responses associated with repeated episodes of severe 
bleeding that might potentially override a putative ‘antihypertensive’ effect of FIX or FVIII 
deficiency. An additional potential target is the GPIbα, the receptor on platelets to which 
thrombin as well as FXI but also the MAC-1 integrin on leukocytes and VWF can bind.
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FXI has a striking homology to pre-kallikrein (PK). Depletion of FXI (e.g. by an ASO 
approach) might cause counter-regulatory upregulation of PK with ensuing activation of 
bradykinin, which might directly cause vasodilation and blood pressure lowering in a nitric 
oxide-dependent manner. It should be evaluated whether targeting of C1-esterase inhibitor, a 
natural FXIa inhibitor, would affect blood pressure. Furthermore, using small molecules 
targeting FXIa92 should be considered to evaluate whether inactivation of the active protease 
is equally effective in influencing blood pressure as the ASO approach. This is of interest, as 
non-specific effects of ASOs on platelet count and function93 could impact on vascular 
function independently of the protease activity of FXI. Datasets of the aforementioned FXI 
ASO clinical trial and population-based cohorts (e.g. Clalit Health Service database,89 
Gutenberg Health Study94) should be explored for associations of FXI activity or single 
nucleotide polymorphisms in the FXI gene with vascular function, hypertension, or incident 
CVD.
Factor XII, Polyphosphates, Prekallikrein and High-Molecular-Weight Kininogen
The FXII-driven contact system and its endogenous activator polyphosphate (polyP) play 
important roles in thrombosis.95 In contrast to FXI deficiency, FXII-deficient humans do not 
suffer from any abnormal bleeding. Targeting the contact system or polyP represents 
promising therapeutic targets for prevention of or interference with thrombotic disorders.
96,97
 In addition, activated FXII induces potent inflammatory responses via activation of the 
kallikrein-kinin system resulting in the formation of the inflammatory mediator bradykinin.
98
 The dual role of FXII in thrombosis and inflammation makes it an attractive therapeutic 
drug target for anticoagulation without any bleeding risks and additional anti-inflammatory 
activities.99,100
Prekallikrein circulates in plasma bound to high-molecular-weight kininogen (HK), the 
bradykinin precursor. Upon activation by FXIIa, prekallikrein is converted to plasma 
kallikrein and then reciprocally amplifies further FXII cleavage that in turn produces 
additional plasma kallikrein.101,102 Similar to FXII, plasma kallikrein-deficient mice have an 
antithrombotic phenotype and do not bleed excessively.103 As plasma kallik-rein functions 
mostly as an amplifier of the coagulation cascade, its deficiency can be overcome by strong 
contact activators which limits its potential use as target for anticoagulation.98 However, 
targeting plasma kallikrein has proven beneficial effects for interference with bradykinin-
driven inflammation such as hereditary angioedema.104,105
Inhibition of HK seems to be another promising strategy for safe thromboprotection as 
suggested from mouse models. In contrast to humans, mice have two kininogen genes and 
ablation of kininogen 1 (mkng1–/– mice) protects from experimental arterial thrombosis 
without causing bleeding.106 Consistently, a patient with plasma kininogen activity of less 
than 1% did not bleed.106 While serine proteases are targetable by small molecule inhibitors 
that bind into the enzymatic pocket, strategies for interference with HK or HK expression 
should be further investigated.
PolyP, a linear polymer consisting of a few to several hundred residues of orthophosphate 
linked by phosphoanhydride bonds, initiates coagulation in a FXII-dependent manner.107 
Platelets contain two pools of polyphosphate. Short-chain soluble polyP with low FXII 
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activating capacity are released from platelet dense granules. The majority of platelet polyP, 
however, forms nanoparticles (similar to other FXII activators such as kaolin or ellagic acid) 
with divalent metal ions (mostly as Ca2+) that are retained on the surface of platelets and 
potently activate FXII.107 The role, structure, and composition of these nanoparticles in 
thrombotic conditions warrant further investigation.
Factor XIII
Factor XIII is unlike other coagulation enzymes in its ability to crosslink, rather than cleave, 
proteins within the clot. FXIII (FXIIIa) activity is essential for clot biochemical and 
mechanical stability.108 Several FXIII polymorphisms appear to modify thrombosis risk;
109,110
 these function, in part, through complex interactions that mediate the kinetics of 
FXIII activation and fibrin crosslinking.111,112 FXIII activity also promotes retention of 
RBCs within clots during platelet-mediated clot contraction.113 However, fundamental 
mechanisms in FXIII biology and biochemistry and its impact on thrombus biophysical 
characteristics remain unclear.
Although studies suggest FXIIIa can be proteolytically inactivated,114 endogenous inhibitors 
of FXIIIa have not been identified. Importantly, currently available FXIIIa inhibitors lack the 
pharmacological properties necessary for in vivo investigations.
FXIII is found in both plasma and cellular compartments, but the relative roles of plasma 
and platelet FXIII in platelet function, fibrin crosslinking, and thrombus composition and 
stability are poorly understood.
Differences in FXIII expression between humans and mice should be considered when using 
animal models.
Fibrin Network Structure
Fibrinogen conversion to fibrin is essential for haemostasis. Formation of clots with 
abnormal structure and stability is associated with haemostatic and thrombotic disorders, 
including both arterial and venous thrombosis/thromboem-bolism.31 Clots with overly dense 
fibrin network structure have been associated with enhanced mechanical and biochemical 
stability and increased risk of thrombosis.65–68 These observations indicate that the clot 
structure may be a biomarker of haemostatic and thrombotic potential.
Most studies use in vitro methods to assess plasma clot structure in the absence of cells, but 
this approach fails to reveal contributions of vascular and blood cells to clot formation and 
function; these include both procoagulant and fibrinolytic activities produced by local blood 
and vascular cells, and mechanical forces imparted by platelets during clot contraction.
Platelet-Fibrin Interactions and Clot Architecture
Knowledge of fibrin interactions with platelets and their respective interactions with other 
blood cells is incomplete. Platelets bind fibrin through activated αllbβ3, which also binds 
fibrinogen. However, recent studies show that fibrin, but not fibrinogen, binds GPVI and 
activates plate-lets.115,116 The thrombus is not homogeneous, but composed of a core of 
strongly activated platelets and a periphery of more loosely activated platelets.117 It is 
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possible that combined collagen and fibrin interactions with platelets drive thrombus core 
formation, while the interaction of fibrin with platelets plays a role in determining the 
thrombus periphery.
1. Filling the void: there is a need for novel in vitro and in vivo models to probe 
interactions between platelets and coagulation. However, studying platelet-fibrin 
interactions is practically challenging, as the fibrin mesh that is formed 
eliminates several techniques. Vice versa, platelet aggregates interfere with 
clotting assays. An intermediate stage of fibrin protofibrils and oligomers 
precede the gelation point.118 Further studies are required to determine platelet 
interactions with these fibrin species.
2. Novel GPVI-fibrin interactions shed new light and should be investigated in 
diseases of thrombosis and haemostasis. Recent data indicate that collagen and 
fibrin bind distinct GPVI epitopes (Onselaer MB et al, PhD, unpublished data), 
suggesting that it is possible to specifically target each ligand interaction. GPVI 
polymorphisms have also been associated with venous thromboembolism in 
genome-wide association studies.119 It would be interesting to investigate 
whether GPVI polymorphisms that result in less active GPVI signaling are also 
associated with decreased fibrin-GPVI interactions.
3. There could be other coagulation and platelet interactions that are currently 
unknown. Proteins such as vWF,120 fibronectin,121 FXIII,122,123 and 
α2−antiplasmin124 are incorporated into the fibrin clot and their role in platelet 
interactions with the clot in the context of the clot network are incompletely 
understood. Furthermore, platelets express several fibrinolytic proteins and FXIII 
on their surface,125,126 which may interact with the surrounding fibrin network.
4. Interactions with red and white cells. There is evidence for the binding of red 
cells to fibrinogen127,128 and platelets.129,130 The implications of these 
interactions deserve further study. Neutrophils contribute to thrombosis through 
the production of NETs.131 DNA and histones have been shown to impart 
resistance to fibrinolysis.132 How DNA and histones interact with fibrin at the 
fibre level is poorly understood. White cell incorporation or invasion into 
thrombi may also contribute to thrombus resolution through the production of 
elastase, which has been shown to degrade fibrin and FXIII.133,134
Recommendations from Theme 3
• Address the relevance of FXI for treatm ent of thrombosis and 
thromboinflammatory disorders; a ‘safe’ lower level of FXI targeting thrombotic 
complications remains to be determined. Off-target effects of inhibiting FXI need 
to be considered.
• Undertake further studies on FXI induced increased thrombin production and 
PAR-mediated cell signaling; these should consider upregulation of PK-mediated 
activation of the bradykinin pathways; population-based cohorts or large trials 
with anticoagulants should be explored for signals of blood pressure lowering 
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effects or changes in incident CVD linked to FXI or other clotting protease 
activity.
• Address the dual role of FXII in thrombosis and inflammation in different 
disorders; investigate strategies for interference with HK or HK expression; 
investigate the role of PolyP nanoparticles on platelets.
• Explore the fundamental mechanisms in FXIII biology and biochemistry and its 
impact on thrombus biophysical characteristics; development of FXIII(a) 
inhibitors would facilitate studies to investigate FXIII(a) function in haemostasis 
and thrombosis.
• Development of technologies to image fibrin structure and biophysical 
characteristics in the presence of blood cells and in thrombi formed in vivo 
would yield important insights; differences in fibrin network structure between 
species (e.g. humans versus mice) should be considered in studies of fibrin 
structure and function in health and disease.
• Study the relationships between abnormal fibrin structure and functional 
consequences, including susceptibility to fibrinolysis and mechanical 
deformability, which should involve new technologies to image fibrin structure 
and biophysical characteristics in the presence of blood cells and in thrombi 
formed in vivo.
• Investigate whether there are additional aspects of the interaction between 
platelets, fibrin (e.g. fibrin-GPVI interactions), and red and white blood cells that 
play key roles in thrombosis and haemostasis.
Preventive and Acute Treatment of Atherothrombosis and Arterial 
Embolism: Novel Ways and Tailoring
Inhibition of Protease-Activated Receptor-Mediated Cell Signalling as Antithrombotic 
Strategy
Despite the prematurely halted TRACER study due to increases in the risk of moderate and 
severe bleeding events in stroke patients, pharmacologic blockade of PAR1 is still 
potentially an attractive target for the prevention of several cardiovascular pathologies, 
including acute coronary syndrome, chronic secondary prevention of ischaemic events, and 
peripheral artery disease (PAD).135,136 In the TRA2 P-TIMI 50 study, the PAR1 antagonist, 
vorapaxar, did meet primary endpoints with significant reductions in major adverse coronary 
events (MACEs) in secondary prevention in nonstroke patients with prior myocardial 
infarction and PAD. In particular, the subgroup of patients with prior MI also demonstrated a 
significant reduction in cardiovascular death and ischaemic events.137 Despite documented 
improvements in MACE reduction and approval by Food and Drug Administration, 
vorapaxar has not seen widespread use, especially in the subjects with prior MI, due to the 
perceived elevated bleeding risk (especially intracerebral haemorrhage). The use of 
vorapaxar on top of dual antiplatelet therapy (e.g. triple antiplatelet therapy) may likely have 
contributed to the increase in incidence of bleeding events. Studying the effects of vorapaxar 
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as monotherapy or dual therapy might reveal reduced bleeding risk and would be worth 
testing especially in subjects with prior MI.
One potential explanation of these increased intracranial bleeds on triple therapy might be 
that akin to TF and thrombomodulin, PAR1 is differentially expressed in endothelial cells of 
the brain,138 thereby giving rise to different integrin/leukocyte adhesion, regulation, and 
haemostatic functions. Another issue with vorapaxar is that it displays functionally 
irreversible binding to PAR1 with pharmacodynamic antiplatelet effects of 4 to 8 weeks.139 
As reversibility is important to mitigate bleeding risk, vorapaxar may not be practical to use 
in patients with heightened risk of bleeding (e.g. older patients, those with low body weight, 
or uncontrolled hypertension). Another interesting pharmacologic effect to be addressed is 
why a single dose of vorapaxar exhibits such a long lasting anti-PAR1 platelet effect well 
after replenishment with fresh platelets 8 to 10 days after drug administration. Does this 
imply that vorapaxar binds to megakaryocyte PAR1 and somehow changes the 
megakaryocyte behaviour leading to a ‘memory’ effect in the megakaryocyte due to 
phenotypic switching or imprinting? Does vorapaxar alter PAR1 expression or are other 
critical platelet signaling components downregu-lated or altered to suppress long-term PAR1 
function in the nascent platelets? The new PAR1 pepducin inhibitor, PZ-128, which has a 
fast on-rate and improved reversibility of recovery of PAR1 platelet function,140 and may 
provide a more favorable balance of efficacy and safety, is currently being evaluated in the 
phase 2 TRIP-PCI clinical trial in the United States.
Aside from PAR1, is the lower affinity PAR4 thrombin receptor inherently a better target 
than PAR1 because PAR4 blockade causes less bleeding, or is PAR4 a poor target because 
PAR1 is the high-affinity thrombin receptor141? Success in targeting PAR4 or the PAR1-
PAR4 heterodimer142 will require achieving efficacy even if safety concerns are not an issue. 
Recent identification of a superactive PAR4 polymorphism in transmembrane domain-2 
(TM2) in blacks would suggest enriching clinical trials with appropriate populations to fully 
understand the pharmacogenomics of PAR4 inhibitors.143
Optimizing Antiplatelet Therapy by Platelet Function Monitoring
Dual-antiplatelet therapy, consisting of aspirin and a P2Y12 inhibitor, is the mainstay of 
treatment for patients with coronary artery disease undergoing percutaneous intervention, to 
prevent stent thrombosis.144,145 However, some patients continue to have thrombotic events 
while on antiplatelet therapy, while others suffer from bleeding.146 The degree of P2Y12 
inhibition as measured by platelet function tests (PFTs) has been related to the risk of both 
thrombotic and bleeding events and has led to the concept of a therapeutic window for 
optimizing antiplatelet therapy.146–148 Several large clinical trials have investigated the value 
of PFT-based tailoring of antiplatelet therapy. These trials, such as GRAVITAS, TRIGGER-
PCI, and ARCTIC, all failed to prove that intensifying P2Y12 inhibitor therapy prevents 
thrombotic events in patients with a low response to P2Y12 inhibitors (high on-treatment 
platelet reactivity [HTPR]).149–151 The ANTARCTIC trial was the first to also include a de-
escalation arm of antiplatelet therapy in cases of low on-treatment platelet reactivity (LTPR) 
to prevent bleeding in the elderly, but this also appeared ineffective.152 Results of the second 
de-escalating trial, TROPICAL-ACS, are expected in the third quarter of 2017.153
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So, have any of these studies actually proven that the concept of individualizing antiplatelet 
therapy based on PFTs does not improve clinical outcome? Members of the workshop felt 
that this cannot be concluded, due to limitations of both the trial designs and PFTs. 
Recognized drawbacks of the trial designs include (1) the study protocols regarding 
intensification of P2Y12 inhibition mainly allowed a singular switch to another drug or dose, 
(2) the studies had low statistical power because of a low incidence of primary endpoints, 
and (3) patients with a higher risk of recurrent events were mostly excluded (e.g. STEMI).
147
 The importance of this last limitation is underpinned by two recent meta-analyses 
indicating that both the predictive value of platelet reactivity for thrombotic events, and the 
benefit of PFT-based tailoring of therapy, is dependent on the patient’s cardiovascular risk 
profile.154,155
Limitations of PFTs also significantly hinder the measurement of platelet reactivity and 
optimization of treatment. Widely used PFTs include light transmission aggregometry 
(LTA), PFA-200, multiplate, and the only true point-of-care test in use, the VerifyNow. Most 
importantly, these assays do not reflect normal physiological platelet function. Platelets tend 
to be activated with single agonists while in vivo multiple stimulation occurs, the influence 
of coagulation or fibrinolysis is not usually assessed, pleiotropic effects of the 
P2Y12−inhibitors cannot be measured, and with the exception of PFA-200 platelet 
aggregation is measured under low shear conditions.156 Another limitation of the widely 
used PFTs concerns the large infl uence of preanalytical variables on the test results, 
including the type of anticoagulant used, delay time from blood withdrawal to measurement, 
and concentrations of agonists used.156 Finally, current PFTs lack assay standardization and 
consensus regarding optimal cut-offs for HTPR and LTPR.147 One of the ongoing activities 
of the ISTH Platelet Physiology SSC is to publish new guidelines for monitoring of 
P2Y12−inhibition (http://www.isth.org/members/group.aspx?id=100371).
Anticoagulation in Atrial Fibrillation: To Treat or Not to Treat, That Remains the Question!
Patients with AF should ideally be treated by a team of cardiologists and specialized 
nurses157–which treats comorbidities and decides on anticoagulation therapy. Current ESC 
guidelines recommend using the CHA2DS2−VASc score to guide initiation of 
anticoagulation therapy in patients with AF.158 However, there is room for improvement in 
the identification of patients who need and tolerate anticoagulation, to prevent overtreatment 
and reduce bleeding events, respectively.
The risk factors that are part of the CHA2DS2−VASc score should be further specified: for 
example, currently it is not defined whether left ventricular hypertrophy on 
echocardiography should be counted as ‘hypertension’ and whether coronary artery disease 
on CT angiography should be counted as ‘vascular disease’.
There is no consensus on the use of anticoagulation in patients with one risk factor 
(CHA2DS2−VASc score of 1 in men, 2 in women). The ESC guidelines suggest considering 
starting anticoagulation,158 while the AHA/ACC suggests considering not to start 
anticoagulation.159 Recent large-scale reports show differing results: there are high stroke 
rates in patients with one risk factor not on anticoagulation,160 while the bleeding 
riskonwarfarin is exceptionally high and probably higher than the stroke risk.161 
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Additionally, AF pattern (i.e. paroxysmal or persistent) may be considered in the decision, as 
it may reflect underlying pathology and hence associate with stroke and bleeding risk.162
Biomarkers may be used to improve risk stratification (e.g. the Age Biomarkers Clinical 
History [ABC] score),163 in which NT-proBNP and troponin are incorporated. However, it is 
currently unknown how this score should be implemented in daily practice.
Both the CHA2DS2−VASc score and the ABC score identify those patients who are 
susceptible to vascular disease, such as stroke, rather than the patient’s clotting tendency. 
However, it has been shown that hypercoagulability may be the underlying process leading 
to AF,164 even in vascularly healthy patients.165 Future risk stratifying strategies may need 
to include measurements of hypercoagulability.
There are several imaging strategies that may enhance identification of patients with a high 
stroke risk. With transoesophageal echocardiography, the presence of high-risk 
echocardiographic features can be assessed,166 while echocardiography, cardiac CT, or MRI 
can be used to assess left atrial appendage morphology,167 all of which may enhance the 
identification of those patients with a phenotype prone to stroke.
Current risk scores are validated only for patients with AF which is recorded on ECG or 
Holter. Cardiac implantable electronic devices (CIEDs) continuously monitor the (atrial) 
heart rhythm. In case a CIED registers an atrial high rate event, it is currently unknown 
whether anticoagulation should be started. The ongoing randomized NOAH 
(NCT02618577) and ARTESiA (NCT01938248) trials will provide valuable answers for this 
category.
How to Handle the Risk of Anticoagulant Therapy?
For many years anticoagulation was based on vitamin K antagonists (VKA). Monitoring of 
anticoagulant treatment is done via regular measurements of the international normalized 
ratio (INR) in a secondary care setting, at least in several countries. These specialized 
anticoagulation centres in which knowledge and experience with VKA treatment is present 
play a key role as coordinator of anticoagulation therapy.
The field of anticoagulation therapy is evolving. Non-VKA oral anticoagulants (NOAC) 
have shown to be at least as effective and safer as VKA in large trials,91,168–170 and are now 
changing clinical practice. Dabigatran, rivaroxaban, apixaban, and edoxaban are replacing 
VKA as first choice treatment for several indications. The possibility to prescribe different 
types of oral anticoagulants for similar indications is making anticoagulant treatment more 
complex.
The balance between the risk of thrombosis and the risk of bleeding remains an important 
concern in patients receiving anticoagulant therapy. Due to a more predictable 
pharmacological profile, routine monitoring is not required for NOACs. However, this 
should not preclude regular follow-up to oversee safety and efficacy of treatm ent.171 
Currently, there is no standardized follow-up available for patients on NOAC therapy. The 
question rises how this follow-up should be implemented in existing health care systems that 
are currently based on VKA management.171,172 We propose a solution for NOAC follow-
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up, designed to increase treatment efficacy and safety, based on expanding the capacity and 
capability of current anticoagulation centres, without a big increase in costs.
The current anticoagulation centres are well trained and equipped to adequately monitor and 
guide patients on VKA, reaching high time in therapeutic range.173 These centres are local 
and give centralized coagulation care to a small population. By educating specialist 
coagulation nurses and physicians, their knowledge on NOACs can be increased. Specific 
software tools and checklists can help nurses with systematic assessm ent of patients on 
NOACs. A physician should be available for consultation, but overall the anticoagulant care 
should, ideally, remain nurse based. Nurses should monitor several aspects, such as the 
following:
• Kidney and hepatic function.
• Compliance to drugs, which can also be checked via information from the 
pharmacy.
• Weight.
• Blood pressure.
• Adverse events during treatment, i.e. bleeding events.
• Haemoglobin and platelet counts.
• Reassessing the indication for anticoagulation.
Furthermore, haemostasis centres are needed, which should be regional and should be 
located in a medical centre with a multidisciplinary team, for example consisting of a 
haematologist, cardiologist, neurologist, and a gastroenterologist.
Organ Specificity of Anticoagulant Effects
The pattern of bleeding with oral anticoagulants differs by agent.174 Compared with 
warfarin, all of the NOACs reduce intracranial bleeding, some NOACs are associated with 
increased gastrointestinal (GI) bleeding, and some are associated with abnormal uterine 
bleeding.175 Several mechanisms have been proposed to explain the organ-specific effects of 
different oral anticoagulants.
First, the mechanisms of action of VKA compared with NOACs: VKA inhibit the 
production of vitamin K-dependent coagulation proteins, whereas NOACs selectively target 
coagulation factors Xa or IIa.176,177 By targeting multiple coagulation factors, VKAs appear 
to produce greater inhibition of thrombin generation than the NOACs,178 which may in part 
explain why they are associated with a higher risk of bleeding. However, this does not 
explain organ-specific differences in bleeding.
The second mechanism is related to physiologic differences between vascular beds of the 
brain, gastrointestinal tract, and uterus. The brain is rich in TF and haemostasis is dependent 
both on expression of TF on subendothelial membranes and on low levels of tissue factor 
pathway inhibitor (TFPI),179 an inhibitor of the TF/VIIa complex. By inhibiting factor VII, 
VKAs prevent the formation of the TF/VII complex and thereby suppress haemostatic 
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mechanisms in the brain, whereas this mechanism is unaffected by the NOACs. This may 
explain the reduction in intracranial haemorrhage with NOACs compared with warfarin. In 
the uterus, animal studies suggest that factor Xa is important in the regulation of 
haemostasis. This may explain why factor Xa inhibition by rivaroxaban is associated with an 
increase in abnormal uterine bleeding compared with warfarin.180
The third mechanism is relevant to excess GI bleeding seen with several NOACs. The 
integrity of the GI mucosa can be disrupted by intraluminal factors,181 and this allows 
uptake of drugs from the lumen. VKAs exert their anticoagulant effect by inhibiting vitamin 
K epoxide reductase, which requires absorption from the gut into the systemic circulation, 
whereas NOACs are only partially absorbed from the gut and residual drug can exert effects 
locally on the GI mucosa leading to bleeding.174,179,182
The ESC guidelines158 for stroke prevention in AF recommend use of the HAS-BLED score 
to predict bleeding, but this score is only weakly predictive. One possible contributor to its 
poor predictive value is that it fails to take into account organ-specific differences in 
bleeding risk. The future development of separate risk scores for intracranial, GI, and uterine 
bleeding may improve risk prediction but might also increase complexity because of 
difficulties in integrating the information for individual patients.
Toward Individualized Optimized NOAC Therapy
Although routine coagulation monitoring is not required in patients taking NOAC, certain 
clinical situations require guidance on the intensity of anticoagulation. Currently, there is no 
consensus on which clinical situations would benefit from such occasional monitoring. 
Some experts propose specific cut-offs in plasma concentration equivalent to reduce the risk 
of haemorrhagic complications in the perioperative setting or to guide the administration of 
reversal agents.183–185
Importantly, these different clinical situations require different test characteristics. For 
emergency situations, the question is whether any remaining anticoagulant effect is still 
present and a sensitive test with short turnaround time and a 24-hour availability is essential. 
Classical coagulation tests, such as PT, aPTT, and thrombin time, have important limitations.
186–188
 For more robust and quantitative purposes, specific assays are available, including 
diluted thrombin time (dTT) or Ecarin chromogenic assay (ECA) for dabigatran, and NOAC 
calibrated chromogenic anti-Xa assays for FXa inhibitors.172,175 The turnaround time of 
these specialized assays is similar to the one of routine tests making them preferable.189 
However, rapid, point-of-care, whole blood tests for use in emergency situations would be 
desirable, while other specialized assays such the thrombin generation test, the 
thromboelastography or ROTEM, and other microfluidic assays might offer potential in the 
near future.190
Laboratory measurement is useful not only in emergency situations but also for eventual 
dose adjustment purposes. Although the clinical trials with NOACs proved the safety of the 
fixed dose policy,91,168–170,191–195 the observed considerable interindividual variation in 
drug levels in pharmaco-kinetic studies and clinical trials suggests that dose adjustment 
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guided by laboratory assays may be appropriate in some circumstances (provided that 
registered doses are used).196–205,a
At present, however, there are neither established therapeutic ranges nor is there evidence-
based data supporting the laboratory approach. At the same time, on-therapy ranges are 
available from the large phase 2/3 studies,201,206–208,b which can be considered in daily 
practice.
Although this proposal did not reach consensus, we propose that future studies should focus 
on the definition of a ‘therapeutic window’, and explore the possibilities of tailoring the dose 
based on these safety margins. This approach may improve the benefit-risk ratio in elderly/
frail patients.
Other New Anticoagulants
The ideal anticoagulant should prevent thrombosis without increasing bleeding risk. 
Additional features could include low renal clearance, minimal drug-drug/drug-food 
interactions, good oral bioavailability, and an effective reversal agent, if required. 
Importantly, the residual major bleeding risk with current anticoagulant drugs is of the order 
of 2 to 3% per year in patients with AF209–211 and 1% in patients with VTE.212 Moreover, 
the number needed to treat with a NOAC for preventing one major bleeding event, compared 
with VKA, remains high (> 100).211,212 Until recently, clinical anticoagulation has been 
oversimplified, without addressing organ-specific processes of bleeding and thrombosis and 
the differences in pathogenesis across various clinical scenarios, as exemplified by bleeding 
patterns with NOACs.211,212 Thus, during drug development, indication-specific targeting 
should be considered. This includes, for example, researching contact pathway inhibition for 
indwelling artificial surfaces such as catheters or mechanical heart valves, and taking into 
account oscillation of drug levels and lack of protective mechanisms present in normal 
vessels walls.
NOACs have yet to challenge VKA treatm ent in rarer sites of thrombosis, such as cerebral 
venous sinus thrombosis and chronic portal vein thrombosis. Patients with mechanical heart 
valves are a group in need of new anticoagulants. The optimal anticoagulant for patients 
with cancer requires further evaluation. Some of these issues may be addressed by clinical 
trials with contemporary anticoagulants already approved for other indications rather than by 
development of new anticoagulants.
Haemostasis and thrombosis are generally considered to be manifestations of the same 
enzymatic and cellular processes. Consequently, dissociation of antithrombotic and bleeding 
aFood and Drug Adm inistration. Eliquis—Clinical Pharm acology and Biopharm aceutics Review(s) 2012 [updated October 25, 
2016]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000ClinPharmRpdf. European 
Medicines Agency. Eliquis—EMEA/H/C/002148/X/04/G 2012 [Available from: http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Assessment_Report_-_Variation/human/002148/WC500136575.pdf].
bEuropean Medicines Agency. Xarelto—Summary of Product Characteristics 2016 [updated October 14, 2016]. Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf; 
European Medicines Agency. Eliquis—Summary of Product Characteristics 2017 [updated February 22, 2017]. Available from: http://
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf; European 
Medicines Agency. Pradaxa—Summary of Product Characteristics 2017 [updated January 12,2017]. Available from: http://
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf.
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effects might not be achievable, except perhaps for the use of anti-FXIIa targeted therapy 
that should, at least from a theoretical point of view, be unaccompanied by a bleeding risk.
100
Recent studies indicate that the ‘anatomy of a clot’ is not homogeneous with 
compartmentalization of a clot into a core and a shell.82 If the anatomy of haemostatic clot 
as opposed to a thrombotic clot is different, it is possible that novel therapeutic molecules 
that are able to exploit such a difference might have a more favorable profile. The recent 
report of a patient with a monoclonal IgA paraprotein targeting thrombin who did not have 
an associated severe bleeding phenotype suggests that it may be possible to target 
components of coagulation with a resultant antithrombotic effect but little if any bleeding 
effect.213 In this patient, the antibody bound to exosite 1 and not the active site of thrombin 
and so there may also be a kinetic basis for an apparent dissociation of effects.
It is important to understand the animal models used to evaluate new anticoagulants. For 
bleeding, the tail transection model214 is frequently used in the preclinical evaluation of 
candidate antithrombotic molecules, but it is problematic because of the effect of 
vasoconstriction and that it is an open rather than a closed bleeding model. The saphenous 
vein bleeding model215 has been suggested as an alternative that may correlate more closely 
with clinical bleeding pheno-type.216 Skin bleeding time is more suited for evaluating 
primary haemostasis (e.g. evaluating antiplatelet medication) but less suited for assessing 
effects of anticoagulants.
To assess effects on arterial thrombosis, ultrasound-induced plaque rupture in the APO-E 
KO mouse has been used as a preclinical model.217 The frequently used ferric chloride-
induced thrombosis model215 recreates a predictive and reproducible thrombus which can be 
subjected to inhibition by various drugs. This can be viewed as a screening procedure, 
selecting drugs only with potential inhibitory activity. However, this model does not indicate 
how a particular drug will work in humans or enable ranking of drugs.
Recommendations from Theme 4
• Study the role of lower affinity PAR4 thrombin receptor vis a vis PAR1 to 
establish whether PAR4 is a better target than PAR1, because PAR4 blockade 
causes less bleeding.
• Develop a practically feasible PFT that reflects in vivo platelet function and 
thrombus formation under physiologic conditions; standardize monitoring of 
P2Y12 inhibition; trials in high-risk patients, using clinically relevant 
physiological PFTs, should be performed to assess the relevance of PFT-based 
tailoring of therapy.
• Refine current risk scores in patients with AF, in particular the decision to start 
anticoagulation in those with low scores; revise CHA2DS2−VASc score and the 
ABC score that includes biomarkers, also taking into account hypercoagulability 
markers; imaging studies may provide additional information in stroke risk.
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• Organize regular follow-up of patients on NOAC treatment in a nurse-based 
manner involving anticoagulation clinics. Regional haemostasis centres can 
manage complex patients in a multidisciplinary manner.
• Develop separate risk scores for intracranial, GI, and uterine bleeding in patients 
on oral anticoagulants to improve risk prediction; this may also increase 
complexity.
• Develop, in those on NOACs, a sensitive test with short turnaround time and 24-
hour availability for emergency situations; dose adjustment guided by laboratory 
assays may be appropriate in some circumstances; the ‘therapeutic window’ 
should be defined, to improve dose fine-tuning.
• Try to target components of coagulation with a resultant antithrombotic effect but 
little, if any, bleeding effect; optimize preclinical testing including a better choice 
in animal models, based on the model’s characteristics related to thrombosis or 
bleeding.
Pleiotropy of Coagulation Proteases, Thrombus Resolution, and Ischaemia-
Reperfusion
Clot Resolution and Ischaemia-Reperfusion Injury
Until recently, thrombectomy was considered an integral part of the treatment strategy for 
acute MI. Recent meta-analyses indicate that this is no longer tenable; only in case of heavy 
thrombus burden may thrombectomy be advantageous albeit at a potential cost of increased 
risk of stroke.218 For acute ischaemic stroke, however, the MR CLEAN study has shown that 
intra-arterial therapy, using for instance stent retrievers, significantly improved patient 
outcome and has since gained status of preferred treatment.219 Thrombectomy results in 
biobanks containing this material and allows analysis of this unique material to further our 
understanding of the thrombotic event and the processes involved in ‘successful’ 
thrombectomy and its sequelae. The following aspects deserve further attention:
Thrombus fragmentation and embolization.—It was deemed important to develop 
new and relevant ways to phenotype the thrombus and determine its source, as current 
strategies seem inadequate. Furthermore, it was considered relevant to study the role of local 
fibrinolysis in embolization and fragmentation and the composition and disease state of the 
atherosclerotic vessel wall.
Stent-Thrombus interaction.—We discussed which processes might play a role in the 
interaction between stent and thrombus;220 two issues were specified: the status of the local 
vasculature and of the coagulation system. With regards to the vasculature at the site of 
thrombectomy, TF content and the depth of injury were considered possible determinants of 
stent-thrombus interaction. Activation of the coagulation system was deemed equally 
important, considering that both ‘erythrocyte-rich’ and ‘platelet-fibrin-rich’ thrombi could 
grow fast, within minutes, while not reflecting thrombus age. Potentially, phenotyping based 
on the relative contribution of the different leukocyte subtypes adds relevant information.
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Biobanking initiatives.—There are many biobanking initiatives but not many specifically 
geared toward arterial thrombosis. Prerequisites for successful biobanks, aside from regular 
ethical considerations, were considered including (inter)national collaboration, thorough 
documentation of the clinical background of thrombus and patient; procedural aspects of 
thrombectomy; standardized and documented protocols for proper handling and storage of 
relevant materials.
The Role of Activated Protein C in Limiting Brain Damage in Ischaemic Stroke
Despite extensive efforts, no novel drug for ischaemic stroke therapy has been approved in 
the past decade. One promising drug candidate currently in phase II clinical studies for 
treatment of ischaemic stroke is the activated protein C (APC) variant 3K3A-APC.221 APC 
provides natural anticoagulant function by inactivating the coagulation cofactors Va and 
VIIIa. In addition, APC conveys direct effects on cells that involve multiple receptors 
including PAR1, PAR3, and the endothelial protein C receptor (EPCR).222 Depending on the 
cell type and cell stress involved, these cellular activities of APC, collectively referred to as 
‘APC’s cytoprotective activities’, can be characterized as antiapoptotic and anti-
inflammatory activity, beneficial alterations of gene expression profiles, protection of 
endothelial barrier function and regenerative activities.
Studies have shown beneficial effects of APC in rodent stroke models.223 The use of 
molecularly engineered APC variants with altered selectivity profiles to rodent stroke 
models, such as the 3K3A-APC variant with minimal anticoagulant activity but normal 
cytoprotective activities, demonstrated that the beneficial effects of APC primarily require 
its cytoprotective activities but not its anticoagulant activities.
Recent insights into the molecular mechanisms for APC’s cytoprotective activities identified 
noncanonical PAR1 and PAR3 activation by APC that give rise to novel tethered ligands 
capable of inducing biased cytoprotective signaling as a key distinction from the traditional 
canonical thrombin-mediated PAR1 and PAR3 signaling that generally results in prohaemo-
static and proinflammatory effects.224 Based on the available data, the consensus model for 
APC’s cytoprotective activities involves the binding of APC to the EPCR which permits 
APC-mediated noncanonical activation of PAR1 at Arg46 and PAR3 at Arg41 resulting in 
the initiation of biased signaling and the corresponding cytoprotective effects. In addition, it 
has become clear that additional receptors including ApoER2, MAC1, PAR2, Tie2, factor V, 
and protein S are involved to provide cell-type-specific variations to this model, but their 
integration into the overall precipitation of APC’s cytoprotective activities remains 
incompletely understood.
Based on the new mechanistic insights, the following research avenues were identified:
1. To determine the effects of anticoagulant drugs on the endogenous protein C 
system and in particular the ability of the endogenous cytoprotective protein C 
pathway to continue to provide beneficial effects on cells and tissues. The 
(patho)physiological generation of APC by thrombin/thrombomodulin may be 
affected by anticoagulant drugs that aim to limit thrombin generation. With the 
increasing use of direct oral anticoagulants (NOACs), questions arise if and how 
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these drugs affect normal APC generation and the ability of APC to provide 
normal cytoprotective effects. Protein C is also sensitive to VKAs as it contains a 
GLA domain that is involved in binding of negatively charged phospholipid 
vesicles required for APC’s anticoagulant activity, binding to EPCR required for 
efficient protein C activation and APC’s cytoprotective effects on cells. Thus, 
questions arise how potential effects of NOACs compare with VKA for protein C 
activation and APC’s cytoprotective effects.
2. There is an urgent need for the development of tools, assays, and the 
identification of biomarkers to evaluate the endogenous cytoprotective protein C 
pathway in patient samples. Assays and tools are available for analysis of the 
anticoagulant protein C pathway, but these cannot be readily extrapolated to 
analysis of the cytoprotective protein C pathway.
3. Basic research is needed to advance our understanding of the molecular 
mechanisms responsible for APC’s cytopro-tective activities. With the notion 
that APC induces non-canonical activation of PAR1 and PAR3, biased signaling, 
and the integration of PAR signaling based on homo- and hetero-dimer 
formation, the realm of possibilities for specialized signaling variations has 
grown exponentially.
New Concept of Thrombolysis and How to Improve Clot Lysis in Ischaemic Stroke
The clinical manifestations of ischaemic stroke are heterogeneous and successful treatment 
depends on many variables involved in thrombus formation such as physical location in the 
brain, time from onset, and patient-specific variables (age, gender, comorbidities, etc.). The 
standard of care for acute ischaemic stroke now involves IV alteplase (recombinant tissue-
type plasminogen activator [tPA]) within 4.5 hours, followed by antiplatelet treatm ent 
(acetylsalicylic acid or clopidogrel) 24 hours after infusion of thrombolytics, to avoid excess 
risk of intracerebral haemorrhage.225,226 The major goal of thrombolytic treatm ent is to 
rapidly establish oxygenated blood flow to limit brain damage. This can be achieved with 
thrombolytic drugs, such as tPA, or by mechanical interventions such as endovascular 
thrombectomy. Mechanical thrombectomy by means of retrievable stents has been proven a 
very effective treatm ent for acute ischaemic stroke caused by large artery thromboembolic 
occlusion219,227–229 and is now accepted as standard treatm ent,230,231 and incorporated in 
major guidelines.232,233 Regarding the use of thrombolytic drugs, the MR CLEAN initiative 
reported that clots could only be lysed in one-third of the patients who were treated with 
recombinant tPA.219 This relatively low success rate has been partly attributed to the fact 
that tPA only accomplishes its thrombolytic effect in small clots because the core of the 
thrombus can be reached.234 Infusion during a longer period of time might improve the 
impact of tPA; however, it may increase the risk of massive brain damage caused by 
bleeding. Meanwhile, proper reperfusion of the brain after endovascular thrombectomy that 
is usually performed on patients with large thrombi is often not achieved, for unknown 
reasons. It has been suggested that the formation/release of micro-thrombi that may diminish 
downstream microvascular per-fusion may play a role.235,236 Nonetheless, reperfusion can 
be visualized and analysed only in the larger vessels. These uncertainties and side effects of 
current treatments for ischaemic stroke highlight the importance of improving drug 
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treatment. The ideal treatm ent should comprise drugs that have immediate effects to 
minimize brain damage, to safely enhance fibrinolysis, and simultaneously do not cause 
bleeding. This kind of treatm ent could be combined with thrombectomy resulting in fast 
mechanical removal of most of the thrombus and fibrinolytic removal of microthrombi.
One novel research avenue is directed at the interaction between vWF and glycoprotein 1b, 
and another approach is to infuse ADAMTS13, and both approaches appear to reduce clot 
stability in models of ischaemic stroke.237,238
Another concept of safe thrombolysis combines profibrinolytic approaches such as anti-
PAI-1, anti-thrombin activatable fibrinolysis inhibitor (anti-TAFI), and anti-α2−antiplasmin.
239
 One promising strategy, for which the proof ofconcept has been demonstrated in mouse 
models, is based on a bispecific diabody against TAFI and PAI-1.240 It simultaneously 
blocks the two antifibrinolytic proteins resulting in a significantly enhanced activity of 
endogenous t-PA. Compared with a monoclonal antibody (150 kDa), it is much smaller (50 
kDa) and thus might be able to reach the core of the thrombus more easily. Additionally, it 
has a half-life of approximately 120 minutes instead of 2 to 3 weeks compared with 
monoclonal antibodies. Therefore, the diabody might be beneficial as a safe fibrinolytic with 
a reduced bleeding risk. Additionally, the possibilities of combining other fibrinolytics, such 
as anti-α2−antiplasmin, with PAI-1 or TAFI still needs to be investigated, as well as 
combining such profibrinolytics with thrombectomy. When designing a factorial ‘cocktail’ 
study, the challenge is to determine the right doses (beneficial effect with minimal harmful 
side effects) of the right combination treatments.
Recommendations from Theme 5
• Organize structured, focused biobanking initiatives to support relevant ways of 
thrombus phenotyping; develop studies to identify vessel wall-stent coagulation/
fibrinolysis interactions.
• Determine the effects of anticoagulant drugs on the endogenous protein C system 
including its cytoprotective effects on cells and tissues; new tools needed to 
evaluate the endogenous cytoprotective protein C pathway in patient samples; 
basic research to advance our understanding of the mechanisms of APC’s 
cytoprotective activities.
• Improve drug treatm ent as well as management of patients suffering from 
ischaemic stroke; the possibilities of combining fibrinolytics, such as anti-
α2−antiplasmin, with PAI-1 or TAFI needs to be investigated, as well as 
combining such profibrinolytics with thrombectomy.
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What is known about this topic?
• Atherothrombosis occurs secondary to atherosclerosis, a chronic infl 
ammatory vascular disease.
• Detailed information on individual risk profiles contributing to 
atherothrombosis is lacking.
• Recent insights in the diversity and functionality of monocytes 
(macrophages), leukocytes, and platelets in driving atherosclerosis and 
subsequent thrombosis have become available.
• This knowledge is poorly implemented in research on atherothrombosis.
• The contact system, factors XI and XIII, and fibrinogen/fibrin are key players 
in determining net coagulation activity.
• Recent insights suggest important interactions with platelets, as well as 
inflammatory mechanisms that link these systems.
• New avenues of antithrombotic management are emerging, but these require 
refinement or tailoring.
• Improved knowledge of PAR-1 and PAR-4 signalling on pathways creates 
opportunities for better tailored therapy.
• Tailoring antiplatelet therapy based on platelet function assays is currently not 
yet feasible.
• Anticoagulation in patients with atrial fibrillation and relatively low-risk 
scores is still unsettled.
• Bleeding risk scores may vary for different organ systems.
• Long-term anticoagulant management, specifically with direct oral 
anticoagulants (DOACs), requires better organization.
• Laboratory testing of DOAC is required under specific conditions.
• Studies on thrombus properties are limited because of poor quality and 
number of biobanking facilities.
• Activated protein C mutants are increasingly interesting for their 
cytoprotective properties (e.g. in the management of patients with ischaemic 
stroke).
• Management of patients with ischaemic stroke merits further refinement 
based on promising outcomes of studies aimed at timely clot removal.
• New developments in the field of improved clot lysis are being explored, but 
the clinical impact has not been addressed yet.
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What does this paper add?
• Specific risk factors like ectopic fat need to be considered.
• Proteomic and metabolomics data should be added to genetic information.
• Better definitions of plaque stability contribution to atherothrombosis are 
needed.
• Mechanisms of leukocyte and macrophage plasticity, migration and 
transformation in murine atherosclerosis need to be considered.
• Disease mechanism-based biomarkers need to be identified.
• Develop experimental systems that incorporate whole blood flow to 
understand how RBCs influence thrombus formation and stability.
• Knowledge on platelet heterogeneity and priming conditions needs to be 
translated toward the in vivo situation.
• The role of factor XI in thrombosis including the lower margins of this factor 
related to safe and effective antithrombotic therapy needs to be established.
• Factor XI is a key regulator in linking platelets, thrombin generation and 
inflammatory mechanisms in a reninangiotensin-dependent manner; the 
impact on thrombin-dependent PAR signaling needs further study.
• The fundamental mechanisms in FXIII biology and biochemistry and its 
impact on thrombus biophysical characteristics need to be explored.
• The interactions of red cells and fibrin formation and its consequences for 
thrombus formation and lysis need to be addressed.
• Platelet-fibrin interactions are pivotal determinants of clot formation and 
stability with potential therapeutic consequences.
• The role of PAR-4 vis a vis PAR-1 as target for antithrombotic therapy merits 
study.
• Ongoing trials on platelet function test-based antiplatelet therapy adjustment 
may support development of practically feasible tests
• Risk scores for patients with AF need refinement, taking new biomarkers 
including for coagulation into account.
• Risk scores that consider organ system differences in bleeding may have 
added value.
• NOAC treatment requires better organization, including education and 
emergency access; laboratory testing still needs rapidly available sensitive 
tests with short turnaround time.
• Biobanks specifically for thrombus storage and analysis are needed.
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• Further studies on novel modified activated protein C-based agents are 
required including its cytoprotective properties.
• New avenues for optimizing treatment of patients with ischaemic stroke are 
needed, also including novel agents that modify fibrinolytic activity (aimed at 
PAI-1 and TAFI) currently studies in subjects with pulmonary embolism.
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Fig. 1. 
Visual representation of the consensus recommendations regarding (1) risk factors, biom 
arkers and plaque insta bility; (2) circulating cells including platelets and atherothrom bosis; 
(3) coagulation proteases, fibrin (ogen) and throm bus form ation; and (4) preventive and 
acute treatment of atherothrombosis and arterial embolism; novel ways and tailoring?
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